<DOC>
	<DOC>NCT02935192</DOC>
	<brief_summary>A Phase 3, double-blind, randomized, placebo-controlled trial of a seasonal, trivalent, split, inactivated influenza vaccine produced by Torlak.</brief_summary>
	<brief_title>Phase 3 Trial of Serbian Seasonal Influenza Vaccine</brief_title>
	<detailed_description>This is a phase 3, double-blind, randomized, placebo- controlled trial with two groups of participants to receive seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or placebo (phosphate buffered saline). A total of about 480 healthy male and female adults 18 through 65 years of age; 320 participants will be randomized to receive vaccine and160 will receive placebo (a 2:1 ratio). At least 25% of the participants (N=120) will be &gt;/= 45 years of age (80 vaccine and 40 placebo recipients). Safety will be assessed in all participants through Day 91. Immunogenicity will be assessed in serum samples obtained at baseline and 21 days after vaccination in a subset of at least 100 individuals randomized to study vaccine and 50 placebo recipients.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 to 65 years old by date of consent Literate (self report) and willing to consent Healthy or medically stable Women of childbearing potential: not breastfeeding or pregnant; willing to use effective contraception to Day 22 Receipt of influenza vaccine within past 10 months Known or suspected congenital or acquired immunodeficiency History of GuillainBarre Hypersensitivity response to previous vaccination Allergic to vaccine components (egg; antibiotics) Any condition, in the opinion of Investigator, that would increase health risk to the participant or interfere with evaluating the study objectives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>seasonal influenza</keyword>
	<keyword>vaccine</keyword>
</DOC>